Clinical effect of trimetazidine in the diagnosis and treatment of ischemic cardiomyopathy and heart failure
缺血性心肌病心力衰竭运用曲美他嗪诊治的临床效果研究

摘要

目的 探讨在缺血性心肌病合并心衰患者治疗中以曲美他嗪实施诊治的价值。方法 试验对象选择于2019.06至2021.12期间，在本院接受治疗干预的缺血性心肌病心衰患者78例，采取数字奇偶法均分为2组，在治疗过程中分别提供常规疗法与联用曲美他嗪，统计施治后两组施治后疗效、心功能与不良反应差异性。结果 经对比组间心功能，观察组左心室舒张末内径、左心室收缩末内径与左心室射血分数指标优于对照组，P＜0.05；经对比组间用药不良反应，观察组与对照组无显著差异，P＞0.05。结论 通过以曲美他嗪实施诊治，可有效改善患者各项临床症状与体征的同时，还能起到增强其心功能作用，且用药安全性较高，适宜临床借鉴与应用。

Abstract

Objective: To explore the value of trimetazidine in the treatment of patients with ischemic cardiomyopathy complicated with heart failure.
Methods: 78 patients with ischemic cardiomyopathy and heart failure who received treatment intervention in our hospital from June 2019 to December 2021 were selected. They were divided into two groups by digital parity method. During the treatment, conventional therapy and trimetazidine were provided respectively. The differences of curative effect, cardiac function and adverse reactions between the two groups were counted.
Results: the indexes of left ventricular end diastolic diameter, left ventricular end systolic diameter and left ventricular ejection fraction in the observation group were better than those in the control group (P < 0.05); There was no significant difference in adverse drug reactions between the observation group and the control group (P > 0.05).
Conclusion  : trimetazidine can not only effectively improve the clinical symptoms and signs of patients, but also enhance their cardiac function. The drug is safe and suitable for clinical reference and application.